Research Article
The Mosaic of “Seronegative” Antiphospholipid Syndrome
Table 4
Autoantibody prevalence in seronegative antiphospholipid syndrome (SN-APS) patients (
) according to the clinical manifestations.
| | Autoantibodies (assay) | Total thrombosis | Arterial thrombosis | Venous thrombosis | Recurrent thrombosis | Pregnancy morbidity |
| | aCL (TLC) | 11 (61.1%) | 7 (58.3%) | 6 (60.0%) | 5 (62.5%) | 3 (37.5%) | | Antivimentin/CL | 7 (38.9%) | 4 (33.3%) | 5 (50.0%) | 3 (37.5%) | 5 (62.5%) | | aCL (TLC) + antivimentin/CL | 12 (66.7%) | 8 (66.7%) | 6 (60.0%) | 5 (62.5%) | 5 (62.5%) | | Antiannexin V | 0 | 0 | 0 | 0 | 1 (12.5%) | | Antiprothrombin | 1 (5.6%) | 0 | 1 (10.0%) | 1 (12.5%) | 2 (25.0%) | | aCL (TLC) + antivimentin/CL + anti-annexin V + antiprothrombin | 13 (72.2%) | 8 (66.7%) | 7 (70.0%) | 6 (75.0%) | 7 (87.5%) | | No autoantibodies | 5 (27.8%) | 4 (33.3%) | 3 (30.0%) | 2 (25.0%) | 1 (12.5%) |
|
|
